H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune DiseaseInterim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with ...
Less than half of the healthcare providers correctly identified refractory chronic cough (RCC) as a cough lasting more than 8 weeks and not responding to treatment, based on survey data from more than ...
AlloCAR70-NKT is an off-the-shelf immunotherapy using engineered immune cells to target kidney cancer without patient-specific customization. The therapy addresses challenges of traditional CAR-T ...
UCLA researchers have developed a new kind of immunotherapy that harnesses the body’s immune system to fight cancer more effectively. The innovative cell therapy uses specially engineered immune cells ...
ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, paving the way for future studies. The updated results from the phase 1 ...
ALLO-316 showed significant activity and safety in patients with metastatic CD70-positive clear cell renal cell carcinoma. ALLo-316, an allogenic CD70-targeting CAR T-cell therapy, showed safety and ...
SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback